Phase 1Status unknown

Topical Cream SNG100 for Treatment in Moderate Atopic Dermatitis Subjects.

A Phase I, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability Profile of Topical Cream SNG100 for 14 Days of Treatment in Moderate Atopic Dermatitis Subjects.

Sponsor
Seanergy Dermatology Ltd. (Industry)
Enrollment
66 planned
Conditions
Atopic Dermatitis
Interventions
Hydrocortisone Acetate 1% Cream; Mometasone Furoate; SNG100
Ages
children, adults, older adults
Registry
NCT04615962

Full record on ClinicalTrials.gov

From the registry

The investigators aimed to understand better the efficacy in a randomized, double-blind, intraindividual design trial in 66 participants with AD treated with SNG100, and 2 different strengths of topical steroids hydrocortisone and the medium potent mometasone furoate cream.

Primary outcomes

  • Side Effects AE's and SAE's

History

  1. Primary completion

  2. Started

  3. Registered